Olin Corporation Stock News

CLAYTON, Mo. , March 25, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today that on Friday, May 2, 2025, at 9:00 a.m.

CLAYTON, Mo. , March 6, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today that General (U.S. Army retired) Edward (Ed) Daly was appointed as a new director by Olin's Board of Directors to serve on Olin's Board effective March 5, 2025.

CLAYTON, Mo. , Feb. 28, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today the pricing of its previously announced private offering (the "Offering") of $600 million aggregate principal amount of 6.625% senior notes due 2033 (the "Senior Notes").

CLAYTON, Mo. , Feb. 28, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today that it intends to offer (the "Offering") $600 million aggregate principal amount of senior notes due 2033 (the "Senior Notes"), subject to market and other conditions.

CLAYTON, Mo. , Feb. 5, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced that its Winchester division, in collaboration with the U.S. Army's Joint Program Executive Office for Armaments and Ammunition (JPEO A&A) and Joint Munitions Command (JMC), celebrated the groundbreaking of the new 6.8mm Ammunition Facility at the Lake City Army Ammunition Plant (LCAAP).

Olin Corporation (NYSE:OLN ) Q4 2024 Earnings Conference Call January 31, 2025 9:00 AM ET Company Participants Steve Keenan - Director of IR Ken Lane - President and CEO Todd Slater - CFO Conference Call Participants Aleksey Yefremov - KeyBanc Capital Markets Mike Leithead - Barclays Hassan Ahmed - Alembic Global Jeff Zekauskas - JPMorgan Bhavesh Lodaya - BMO Capital Markets Patrick Cunningham ...

Highlights Fourth quarter 2024 net income of $10.7 million, or $0.09 per diluted share Quarterly adjusted EBITDA of $193.4 million CLAYTON, Mo. , Jan. 30, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced financial results for the fourth quarter ended December 31, 2024.

London, U.K., January 27 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “the Company”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, today emerges from stealth mode and announces the appointment of Martin Olin as Chief Executive Officer.